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Abstract
Objective—Major depressive disorder (MDD) is a common disorder among adolescents. The 
Treatment for Adolescents with Depression Study (TADS) was a randomized-controlled trial to 
examine the efficacy of fluoxetine and cognitive-behavioral therapy (CBT), separately and 
together, compared with placebo, in adolescents ages 12–17 years. The Survey of Outcomes 
Following Treatment for Adolescent Depression (SOFTAD) was designed as a naturalistic follow-
up of participants in TADS. The aims of the current analyses are to describe mental health service 
use during the SOFTAD period.
Method—196 adolescents were recruited from twelve TADS sites. The Schedule for Affective 
Disorders and Schizophrenia for School-Age-Children-Present and Lifetime Version was used for 
clinical diagnoses. Participants completed a psychiatric treatment log and the Child and 
Adolescent Services Assessment to assess service use.
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Results—58% received psychotherapy or non-stimulant psychotropic medication during 
SOFTAD. Youth with recurrent MDD had higher rates of treatment compared to youth without 
recurrent MDD (71% vs. 45%). However, nearly one-third of the adolescents in the study did not 
receive treatment for a recurrent episode of depression. Service use differed by gender for those 
with recurrent MDD, with females (79%) receiving treatment at higher rates than males (55%), 
although there was no significant difference in depression severity between genders. Younger 
participants with recurrent MDD had higher odds of receiving psychotherapy.
Conclusions—Use of psychotherapy and psychotropics following recurrence of depression 
appears to be influenced by age and gender. Even when youth respond well to treatment, a 
sizeable percent are likely to experience a subsequent episode that may go untreated.
Keywords
Adolescents; major depressive disorder; mental health services
Major depressive disorder (MDD) is one of the most common disorders among adolescents, 
with prevalence estimates of approximately 5.9% for females and 4.5% for males (Costello, 
Erkanli, & Angold, 2006). Both cognitive-behavioral therapy (CBT) and certain selective 
serotonin reuptake inhibitor (SSRI) antidepressants are established treatments for adolescent 
MDD. The Treatment for Adolescents with Depression Study (TADS) was a randomized-
controlled trial to examine the short-term efficacy of the SSRI fluoxetine and CBT, 
separately and together, compared to clinical management with a pill placebo; and their 
longer-term efficacy compared to one another. To summarize TADS findings, at three 
months combination therapy was the most efficacious short-term treatment, all three 
treatments had equivalent response rates at nine months, by which point combination proved 
most cost-effective because of reduced psychiatric hospitalization (Domino, Foster, et al., 
2009; TADS Team, 2004; 2007).
Despite efficacious depression treatments, studies show that a sizeable number of 
adolescents experience a recurrent Major Depressive Episode (MDE) (Weller & Weller, 
2010). During TADS and its follow-up study (Survey of Outcomes Following Treatment for 
Adolescent Depression; SOFTAD), 44.6% of the original TADS sample were followed for a 
total of five years. As reported elsewhere 96.4% recovered from their index MDE, but 
46.6% of recovered adolescents had a recurrent MDE (Curry et al., 2011). Thus, response to 
depression treatment does not necessarily impart long-term protection from recurrence. 
Other research indicates a substantial percentage of adolescents treated in clinical trials for 
MDD receive additional services subsequently: Brent and colleagues (1999) reported that 
42.1% received additional treatment within just two years following a psychotherapy trial.
The goal of the current analyses was to examine mental health services received by TADS 
participants during the SOFTAD follow-up period. Domino, Burns, and colleagues (2009) 
examined service use among TADS participants 3 months prior to randomization, and found 
that less than one third (29.3%) had seen a mental health specialist or medical provider for 
behavioral health reasons. This rate of service use is lower than a national estimate of 40% 
for annual mental health service use for adolescents experiencing a MDE (SAMHSA, 2005), 
although it covers a much shorter time period; but it is higher than estimates of mental 
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health service use among adolescents in the general population, which range from 3 to 7% 
(Domino, Burns et al., 2009). Because the adolescents in the sample had subsequently 
participated in a randomized-controlled trial of evidence-based interventions for MDD, it 
was hypothesized that they would receive similar services during the follow-up at relatively 
high rates due to familiarity with mental health providers and services, especially in cases of 
recurrent MDD. Specifically, among those who experienced recovery from MDD, it was 
hypothesized that receipt of mental health services would be higher for those with a 
recurrence. In addition, the current analyses also examined factors potentially associated 
with mental health treatment, including age, gender, social-environmental factors, 
depression severity, and the presence of non-MDD psychiatric disorders. These factors were 
examined separately for adolescents with recurrent versus non-recurrent MDD because of 
the potential for differential effects in these two subsamples. Because previous investigation 
of the sample documented no differences in rates of mental health service use based on 
TADS treatment arm (Curry et al., 2011), those analyses are not included in the current 
paper.
Method
The design, sample characteristics, and outcomes of TADS and SOFTAD have been 
described previously (Curry et al., 2011; TADS Team, 2004; 2007; 2009). Briefly, TADS 
participants (N = 439) were randomized to a 12-week intervention of fluoxetine, CBT, their 
combination, or pill placebo. Those who responded at least partially to any of the three 
active treatments then proceeded to 6 weeks of continuation and 18 weeks of maintenance 
treatment, whereas non-responders were referred to community treatment. Placebo 
participants were then offered 12 weeks of active treatment unless they were full responders 
without relapse. After week 36, all adolescents were followed openly for one year. SOFTAD 
was then an additional open follow-up extending 3.5 years after the end of the TADS 
follow-up year. Therefore, the total TADS-SOFTAD period encompassed 63 months: nine 
months of TADS treatment, 12 months of TADS follow-up, and 42 months of SOFTAD 
follow-up.
Participants
All TADS participants were eligible for SOFTAD, regardless of initial TADS treatment 
assignment or response. SOFTAD participants were 196 adolescents (44.6% of TADS 
sample) recruited from twelve of thirteen TADS sites. The Duke University Medical Center 
and site institutional review boards approved this study, and written consent or assent was 
obtained from participants and parents. The SOFTAD participants have previously been 
described and compared to non-participating TADS subjects (Curry et al., 2011). They were 
56.1% female, with a mean age of 17.8 (SD = 1.8 years) at time of initial SOFTAD visit. 
They differed from non-participants on age at TADS baseline (slightly younger); ethnicity 
(fewer minority adolescents); and comorbidity (fewer comorbid diagnoses). More of them 
had been in their initial MDD episode at TADS baseline. Only seven SOFTAD participants 
(3.6%) failed to attain remission from their index MDD episode, and these adolescents were 
excluded from analyses below comparing recurrent and non-recurrent depression subjects.
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Initial SOFTAD visit optimally occurred 27 months after TADS baseline; however, 
participants’ first assessment actually occurred at the closest point to their recruitment into 
SOFTAD. Participants could complete up to seven SOFTAD assessments at 6- or 12-month 
intervals, five of which included diagnostic interviews administered by independent 
evaluators and two were comprised of mail-in questionnaires. Of the diagnostic interviews, 
58% of participants completed the first assessment, while 68–70% completed the remaining 
four. In months since TADS baseline, points of entry for SOFTAD participants were 
distributed as follows: month 27 (33.7%); month 33 (21.9%); month 39 (13.8%); month 45 
(10.7%); month 51 (9.7%); month 57 (8.2%); month 63 (2.0%). Females were more likely 
than males to complete the final assessment at month 63 (OR = 2.10, 95% CI: 1.11 – 3.97, p 
< .05), but age was not associated with study completion (OR = 1.12, 95% CI: 0.94 – 1.32, p 
= .20).
Measures
Schedule for Affective Disorders and Schizophrenia for School-Age-Children-
Present and Lifetime Version (K-SADS-P/L)—The K-SADS-P/L (Kaufman et al., 
1997) was administered during TADS and SOFTAD to determine major depression and 
other disorders using DSM-IV criteria (American Psychiatric Association, 2000), and to 
determine recovery from and recurrence of major depressive episodes. Recurrence was 
defined as a new episode following at least eight weeks with no MDD symptoms.
Clinical Global Impression-Severity Scale (CGI-S)—The CGI-S (Guy, 1976) is a 1 
to 7 rating scale, indicating current severity of depression, where 1 = normal, 3 = mild, 4 = 
moderate, etc. The independent evaluators completed the CGI-S following administration of 
the K-SADS-P/L. The highest CGI-S score obtained at any assessment was used as the 
depression severity index in the present analyses.
Psychiatric Treatment Log (PTL)—With the assistance of the site study coordinator, 
participants and/or parents completed a record of psychotherapy and psychotropic 
medication received since the last TADS or SOFTAD visit on the PTL, a form created for 
this study. This format was chosen to minimize missing data if participants did not complete 
all assessments. Psythotherapy categorizations were determined by participants with the aid 
of staff. Data were coded into “yes” (1) or “no” (0) binary indicator variables for (1) 
psychotherapy; (2) non-stimulant medication; (3) any psychotherapy and/or medication; and 
(4) both psychotherapy and medication to indicate whether the service was used at any time 
during SOFTAD. Psychotherapy types included cognitive-behavioral, family, group, 
interpersonal, and supportive therapies. Non-stimulant medication categories included 
antidepressants, antipsychotics, anxiolytics, and mood stabilizers.
Child and Adolescent Services Assessment (CASA)—Participants completed a 
modified version of the CASA (Ascher, Farmer, Burns, & Angold, 1996; Farmer, Angold, 
Burns, & Costello, 1994) to assess receipt of more intensive services (inpatient psychiatric 
hospitalization; residential group home or treatment center care) within the past six months. 
The CASA has good to excellent test-retest reliability and very good correspondence with 
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provider records (Ascher et al., 1996; Bussing, Mason, Leon, & Sinha, 2003). A binary 
indicator variable was created for each type of intensive service indicating whether it had 
been received at any assessment point.
Social-environmental factors
At the initial SOFTAD visit, site study coordinators interviewed the parent of minor 
participants or the young adult participants and coded whether or not the participant was 
enrolled in an educational program, living at home, and employed part- or full-time.
Analytic methods—Analyses were run in StataSE 11 (StataCorp., 2009) or SPSS 14.0 
(SPSS Inc., 2005). Chi-square goodness-of-fit analyses were used to compare rates of 
mental health use between adolescents with recurrent versus non-recurrent MDD. 
Multivariate logit analyses examined mental health service use as the dependent variable. 
Predictors included age, gender, social-environmental factors, highest CGI-S severity score, 
the presence of a non-MDD diagnosis at any SOFTAD assessment point, and completion of 
the final study assessment point. General linear models were run to compare CGIS severity 
scores for males and females.
Results
Among the 196 adolescents in the sample, the majority (58.7%) received psychotherapy or 
non-stimulant psychotropic medication during SOFTAD, which included antidepressants, 
antipsychotics, anxiolytics, and mood stabilizers (Table 2). Psychotherapy and medication 
were used at similar rates (42.3 and 46.4%, respectively), with 30.1% of adolescents 
receiving both psychotherapy and medication across the SOFTAD period. Despite previous 
exposure to CBT by TADS participants, the most commonly received psychotherapy was 
supportive therapy (21.4%), followed by CBT (11.2%). As previously reported (Curry et al., 
2011), antidepressants were the most commonly used medication with 88 adolescents 
(44.9%) reporting their use. Regarding intensive mental health services, 8.7% received 
inpatient psychiatric treatment and 3.6% reported placement in a residential treatment center 
or group home. All of the adolescents receiving intensive services also received 
psychotherapy and/or non-stimulant medication. Because of the small number receiving 
intensive services, these services were not included in additional analyses.
Not surprisingly, youth with recurrent MDD had higher rates of psychotherapy and/or 
medication compared to youth without recurrent MDD (Χ2 (1) = 13.07, p < .001), with 
71.6% of those with recurrent depression receiving psychotherapy and/or medication 
compared to 45.5% of those without (see Table 3). These data indicate that although a high 
percentage of adolescents received medication and/or psychotherapy, 28.4% of those with a 
recurrent episode of MDD did not receive either treatment despite previous involvement in 
the TADS trial.
Service use also differed by gender for those with recurrent MDD, with females receiving 
treatment at significantly higher rates (78.7% of females versus 55.6% of males; Χ2 (1) = 
4.92, p < .05), despite no gender difference in highest depression severity (t (86) = −1.26, p 
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= .10). In contrast, among those without recurrent MDD, males (43.6%) and females 
(47.8%) received treatment at similar rates (Χ2 (1) = .177, p = .67).
Table 4 presents multivariable logistic regression models stratified by recurrent or non-
recurrent MDD, with psychotherapy and/or medication, psychotherapy, or non-stimulant 
medication entered as binary dependent variables, and highest depression severity, gender, 
and age entered simultaneously as predictors. Because females were more likely than males 
to complete the final SOFTAD assessment, a dichotomous variable for study completion 
was also included in the model. The model with any treatment (psychotherapy and/or 
medication) as the dependent variable resulted in no significant findings for either the 
recurrent or non-recurrent MDD groups. Similar multivariable models were run for 
psychotherapy and non-stimulant medication separately. In the recurrent group, 
psychotherapy was associated with higher depression severity (OR = 1.33, 95% CI: 1.00 – 
1.77, p < .05) and younger age (OR = .70, 95% CI: .54 – .92, p = .01), and medication was 
associated with female gender (OR = 3.18, 95% CI: 1.22 – 8.30, p < .05). In contrast, among 
participants in the non-recurrent group, only depression severity was associated with receipt 
of psychotherapy (OR = 1.71, 95% CI: 1.06 – 2.79, p < .05), and younger age was associated 
with medication use (OR = 0.73, 95% CI: 0.56 – 0.96, p < .05).
We next ran separate multivariable models including educational status, employment status, 
and living at home as covariates, severity, gender, age, and study completion entered 
simultaneously as additional predictors, and any psychotherapy and/or medication use as the 
dependent variable. Only enrollment in school was significantly associated with higher odds 
of services (OR = 3.46, 95% CI: 1.46 – 8.16, p < .01). Because of potential age effects for 
the social-environmental covariates, two additional models were run for those ages 14–17 at 
baseline and those 18-years and older. For the younger participants, none of the social-
environmental variables were associated with treatment. For participants 18-years or older at 
baseline, enrollment in school remained the only factor associated with higher odds of 
receiving treatment (OR = 3.98, 95% CI: 1.16 – 13.7, p < .05).
Finally, we explored the effect of having a non-MDD psychiatric disorder (other 
internalizing, disruptive behavior, eating or substance use disorder) on receipt of treatment. 
Among youth with recurrent MDD, over two-thirds (72.7%) had a non-MDD diagnosis, 
with other internalizing (58.0%) and substance use disorders (30.7%) being the most 
prevalent. However, this was not associated with increased odds of receiving psychotherapy 
and/or medication (OR = 1.13, 95% CI: .38 – 3.43, p = .81). For those without recurrent 
MDD, approximately half (51.5%) had a non-MDD diagnosis, with other internalizing 
(37.6%) and disruptive behavior disorders (17.8%) most prevalent. Having a non-MDD 
disorder was associated with use of psychotherapy and/or non-stimulant medication, even 
when accounting for depression severity, gender, and age (OR = 4.11, 95% CI: 1.56 – 10.83, 
p < .001).
Discussion
We followed a sample of depressed adolescents, examining psychotherapy, 
pharmacotherapy and intensive mental health service use following participation in a large, 
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national clinical trial. Previous research has indicated that the original TADS sample was 
broadly representative of depressed American adolescents on gender, age, and majority-
minority ethnicity distribution, but with a relative underrepresentation of adolescents from 
low income families (TADS Team, 2005). On most dimensions the SOFTAD sample was 
similar to the overall TADS sample. Entry into TADS required stable, functionally 
impairing MDD: the major reason for exclusion was insufficient or unstable severity of 
depression at baseline (TADS Team, 2005). Because TADS participants were enrolled in a 
clinical trial, they may have been more likely to seek treatment than the broader group of 
community adolescents. Thus, the results of the present study are generalizable to treatment-
seeking adolescents with stable moderate to severe MDD, at least to those from middle or 
higher income families.
The majority (58.7%) of youth in the SOFTAD sample received psychotherapy and/or non-
stimulant psychotropic medication during the follow-up period, with 42.2% receiving 
psychotherapy and 46.4% taking non-stimulant medication. The severity of depressive 
symptoms was associated with receipt of services for both the recurrent and non-recurrent 
MDD groups. Thus, whether or not diagnostic criteria were met for MDD, adolescents with 
greater clinical severity had higher odds of receiving treatment. Even when accounting for 
age and gender, depression severity was associated with higher odds of psychotherapy for 
both recurrent and non-recurrent groups, and associated with higher odds of medication 
and/or psychotherapy for the non-recurrent group.
Despite the overall high rates of treatment, significant differences in the use of services 
emerged, particularly among the youth who experienced a recurrence of MDD. Specifically, 
males with recurrent MDD had significantly lower odds of receiving treatment, with just 
over half (55.6%) reporting use of psychotherapy and/or medication. This finding appeared 
to be driven by significantly lower odds of males receiving psychotropic medication. 
Although a relatively high proportion of females (78.7%) received treatment, one fifth did 
not. Thus, even with prior exposure to evidence-based treatment for MDD, a sizable 
proportion of adolescents of both genders did not receive treatment for a subsequent episode 
of MDD. Nonetheless, an effect of participation in the clinical trial is very likely. Among 
U.S. adolescents with a past year episode of MDD only 37.7% of males and 41.3% of 
females ages 12–17 received mental health treatment (SAMHSA, 2005). Similarly, among 
U.S. college students and other young adults ages 18–22 with a past year episode, 43.9% 
and 40.4%, respectively, received specialty mental health care services (SAMHSA, 2012), 
whereas 62.5% of male and 70.6% of female SOFTAD participants ages 18–22 with 
recurrent depression received mental health treatment over the follow-up period. Although 
rates of service use in the SOFTAD sample were high, they were lower than the 92% rate 
reported by Goldston and colleagues (2003) for formerly psychiatrically hospitalized 
adolescents in a longer (up to 8-year) follow-up, perhaps because of the more severe nature 
of psychiatric impairment in the latter sample. Our findings that service use was higher 
among those with recurrent MDD and among those with co-morbid disorders for those 
without recurrent MDD, are similar to those of Brent and colleagues (1999). In their clinical 
trial follow-up, additional treatment was associated with more severe depression and with 
the presence of disruptive behavior disorders.
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Intensive services were used at relatively high rates by the SOFTAD participants, with 8.7% 
experiencing psychiatric hospitalization and 3.6% receiving treatment in a residential or 
group home facility. These rates exceed the national estimates (2% for a hospital admission 
and 1% for other residential care) for adolescents with emotional and behavioral problems 
(SAMHSA, 2008). Indeed, our rates may have been an underestimate, as we inquired about 
such services only within the six months preceding each completed SOFTAD assessment.
Even with the wide age range of our participants (14–22 years at SOFTAD entry), no 
significant age differences emerged for receipt of “any treatment” (psychotherapy and/or 
non-stimulant medication); however, the odds of receiving psychotherapy significantly 
declined among older adolescents with recurrent MDD. This difference could be accounted 
for by a slight increase in medication rates by age, or resistance among adolescents to 
participating in therapy. However, among those with non-recurrent MDD, younger age was 
associated with medication use. These age differences are in contrast to those reported by 
SAMHSA for national samples indicating that older adolescents receive services at 
comparable rates to younger adolescents. Because information about insurance coverage 
was not collected, the role of private insurance in treatment receipt could not be examined. 
Of the social-environmental factors examined, enrollment in school was the only one 
significantly associated with receiving psychotherapy and/or medication, and this finding 
continued to be significant for the older adolescents aged 18 and older at the time of entry 
into SOFTAD when analyzed separately from the younger participants. This may be due to 
the increased availability of services in school and college settings.
Several limitations of the current study should be noted. The adolescents in the three active 
treatment conditions during TADS had received evidence-based psychotherapy and/or 
pharmacotherapy for MDD during the study, and over half of the placebo group received 
study treatments after the blind was broken (Kennard, Silva, Mayes et al., 2009). Thus, the 
study examines service use among a group of adolescents with an optimized experience with 
mental health treatment who were enrolled in a clinical trial, and TADS participants are not 
necessarily representative of all depressed adolescents. The adolescents in the SOFTAD 
sample were predominantly White and from middle class backgrounds so findings may not 
generalize to more diverse populations. Even within the SOFTAD sample, access to quality 
mental health services likely varied among participants, and factors such as coverage by 
private insurance were not measured. Finally, the effect of missing data was minimized 
through the PTL assessment method and by including an indicator of study completion in 
the multivariable model. However, the effects of missing study data may not be fully 
accounted for in study findings, and the PTL was created for this study and not subjected to 
independent validity testing.
Nevertheless, the findings of the current study are clinically relevant. Even when youth 
recover after treatment for MDD, a sizeable percent are likely not to obtain treatment for a 
recurrent episode, particularly among male adolescents. Long-term monitoring of depressive 
symptoms and need for services is indicated, and may include periodic check-ins with a 
mental health specialist, primary care physician, or school personnel. Primary care 
physicians, however, may not adequately recognize or treat adolescent depression. Domino, 
Burns, and colleagues (2009) found that in the 3 months prior to the TADS study, a sizable 
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proportion of the adolescents had been in contact with a physician but did not receive mental 
health treatment. Providing adolescents and their parents with information about the 
likelihood of recurrence and possible symptoms to watch for could facilitate the 
identification of recurrent symptoms, as could additional training for primary care 
physicians/clinicians. Education about how to locate appropriate services if symptoms 
reappear would also be beneficial, particularly for older adolescents who are not associated 
with academic programs. In addition, periodic “booster” sessions with mental health 
providers may be needed to ensure that recurrent depressive disorder and comorbid 
conditions are identified and treated.
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Table 1
Characteristics of SOFTAD Adolescents at Enrollment
Variable
Total (N = 196)
n %
Age at SOFTAD enrollment (M±SD) 17.8±1.8
Race
 White 154 78.6
 African-American 16 8.2
 Latino 18 9.2
Female 110 56.1
Enrolled in school 159 81.5
Living at home 168 86.2
Employed 88 44.9
Recurrent MDD 88 46.6
Non-MDD psychiatric disorder during SOFTAD period 121 61.7
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Table 2
Services Received by SOFTAD Participants across All Assessments (N = 196)
Mental health service n %
Psychotherapy 83 42.3
 Cognitive-behavioral therapy 22 11.2
 Family therapy 7 3.6
 Group therapy 11 5.6
 Interpersonal therapy 15 7.6
 Supportive therapy 42 21.4
Non-stimulant medication 91 46.4
 Antidepressants 88 44.9
 Antipsychotics 16 8.2
 Anxiolytics 6 3.1
 Mood stabilizers 13 6.6
Medication and psychotherapy 59 30.1
Medication and/or psychotherapy 115 58.7
No medication or psychotherapy 81 41.3
Psychiatric inpatient treatment 17 8.7
Residential/Group home 7 3.6
Treatment among ages 14–17 (n = 91)
 Medication and/or psychotherapy 61 67.0
 Psychotherapy 46 50.5
 Non-stimulant medication 47 51.6
Treatment among ages 18–22 (n = 105)
 Medication and/or psychotherapy 51 48.6
 Psychotherapy 37 35.2
 Non-stimulant medication 44 41.9
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Table 3





n % n %
Psychotherapy 50 56.8 30 29.7
Non-stimulant medication 53 60.2 32 31.7
Any treatment 63 71.6 46 45.5
No treatment 25 28.4 55 54.5
Both psychotherapy and medication 40 45.4 16 15.8
Intensive services (acute and residential treatment) 11 12.5 5 5.0
Note: Index MDE = Major Depressive Episode at TADS baseline
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